Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational

biopharmaceutical A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, t ...

company A company, abbreviated as co., is a Legal personality, legal entity representing an association of legal people, whether Natural person, natural, Juridical person, juridical or a mixture of both, with a specific objective. Company members ...

headquartered in

Thousand Oaks, California Thousand Oaks is the second-largest city in Ventura County, California, located in the northwestern part of Greater Los Angeles. Approximately from the city of Los Angeles and from Downtown Los Angeles, it is named after the many oak trees pr ...

. As one of the world's largest independent

biotechnology Biotechnology is a multidisciplinary field that involves the integration of natural sciences and Engineering Science, engineering sciences in order to achieve the application of organisms and parts thereof for products and services. Specialists ...

companies, Amgen has approximately 24,000 staff in total as of 2022. The name "AMGen" is a

portmanteau In linguistics, a blend—also known as a blend word, lexical blend, or portmanteau—is a word formed by combining the meanings, and parts of the sounds, of two or more words together.

of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its

initial public offering An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail (individual) investors. An IPO is typically underwritten by one or more investm ...

). The company is listed on the Nasdaq Global Select Market under the ticker symbol "AMGN", as well as a component of the

Nasdaq-100 The Nasdaq-100 (NDX) is a stock market index made up of equity securities issued by 100 of the largest non-financial companies listed on the Nasdaq stock exchange. It is a modified capitalization-weighted index. The stocks' weights in the inde ...

, the

Dow Jones Industrial Average The Dow Jones Industrial Average (DJIA), Dow Jones, or simply the Dow (), is a stock market index of 30 prominent companies listed on stock exchanges in the United States. The DJIA is one of the oldest and most commonly followed equity indice ...

, and the

S&P 100 The Standard and Poor's 100, or simply the S&P 100, is a stock market index of United States stocks maintained by Standard & Poor's. The S&P 100 is a subset of the S&P 500 and the S&P 1500, and holds stocks that tend to be the largest and most ...

and 500 indices.

History

Amgen was established in Thousand Oaks in 1980, as Applied Molecular Genetics.Baker, Pam (2002). ''Thousand Oaks Westlake Village: A Contemporary Portrait''. Community Communications, Inc., p. 37. . Amgen was backed by a small group of venture capitalists, and its early focus was on

recombinant DNA Recombinant DNA (rDNA) molecules are DNA molecules formed by laboratory methods of genetic recombination (such as molecular cloning) that bring together genetic material from multiple sources, creating sequences that would not otherwise be fo ...

technology and recombinant human

insulin Insulin (, from Latin ''insula'', 'island') is a peptide hormone produced by beta cells of the pancreatic islets encoded in humans by the insulin (''INS)'' gene. It is the main Anabolism, anabolic hormone of the body. It regulates the metabol ...

. Its initial scientific advisory board consisted of Norman Davidson, Leroy Hood, Arnold Berk, John Carbon, Robert Schimke, Arno Motulsky, Marvin H. Caruthers, and Dave Gibson. In October 1980, Amgen named George Rathmann its first president and chief executive officer. On June 17, 1983, Amgen went public, selling two million

common shares Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States. They are known as equity shares or ordinary shares in the UK and other Com ...

and raising nearly $40 million. That same year, after more than two years of work, an Amgen research team led by Fu-Kuen Lin had a breakthrough in finding and cloning the

erythropoietin Erythropoietin (; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys in response to cellular hypoxia; it stimulates red blood cell production ( erythropoiesis) in th ...

gene, a protein created in the kidney that stimulates

red blood cell Red blood cells (RBCs), referred to as erythrocytes (, with -''cyte'' translated as 'cell' in modern usage) in academia and medical publishing, also known as red cells, erythroid cells, and rarely haematids, are the most common type of blood cel ...

production. Lin's team created what would become Epogen (

epoetin alfa Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. Epoetin alfa is an erythropoiesis-stimulating agent. It stimulates erythropoiesis (increasing red ...

). 1984: In June, Amgen and Kirin formed a joint venture giving Kirin the rights to Epogen in Japan. A year later, Amgen researcher Larry Souza and his team cloned

granulocyte colony-stimulating factor Granulocyte colony-stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. Function ...

(G-CSF), leading to the development of Neupogen (

filgrastim Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low neutrophil count. Low neutrophil counts may occur with HIV/AIDS, following chemotherapy or radiation poisoning, or be of an unknown cause. It may ...

). In October 1988, Gordon Binder was named CEO, succeeding George Rathmann. The following year, in 1989, Amgen received approval for the first recombinant human erythropoetin product, Epogen (

). In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy. Amgen opened a new manufacturing facility in

Puerto Rico ; abbreviated PR), officially the Commonwealth of Puerto Rico, is a Government of Puerto Rico, self-governing Caribbean Geography of Puerto Rico, archipelago and island organized as an Territories of the United States, unincorporated territo ...

, in March 1993, which later became the company's flagship manufacturing site. In 1994, Amgen became the fifth company to receive the U.S. Department of Commerce's

National Medal of Technology and Innovation The National Medal of Technology and Innovation (formerly the National Medal of Technology) is an honor granted by the president of the United States to American inventors and innovators who have made significant contributions to the development ...

, in recognition of its work developing medicines to improve quality of life for kidney and cancer patients. Also around this time, Amgen researcher Steve Elliott and his team added more sugar molecules to erythropoietin, causing it to remain in the body longer. This led to the development of Aranesp ( darbepoetin alfa).

2000-2014

Binder was succeeded as CEO by Kevin W. Sharer in 2000. Robert A. Bradway became Amgen's president and chief executive officer in May 2012, following Sharer's retirement. June 6, 2010, Amgen received

FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...

approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis. In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%. In November 2010 the

approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors. The clinical trials primarily enrolled patients with breast or prostate cancer. In March 2011, Amgen acquired a manufacturing facility near Dublin, Ireland, in March. Amgen also opened an affiliate in China in 2013. In November 2014 the company announced it was halting all trials of rilotumumab in advanced

gastric cancer Stomach cancer, also known as gastric cancer, is a malignant tumor of the stomach. It is a cancer that develops in the lining of the stomach. Most cases of stomach cancers are gastric carcinomas, which can be divided into a number of subtypes ...

patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without. Later in the same week, the company in conjunction with

AstraZeneca AstraZeneca plc () (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas includi ...

reported positive results for

brodalumab Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. In February 2017, it received US FDA approval to treat moderate to severe plaque ...

in a Phase III trial comparing the compound with

ustekinumab Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication used for the treatment of Crohn's disease, ulcerative colitis, Psoriasis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23. ...

and a

placebo A placebo ( ) can be roughly defined as a sham medical treatment. Common placebos include inert tablets (like sugar pills), inert injections (like saline), sham surgery, and other procedures. Placebos are used in randomized clinical trials ...

in treating

psoriasis Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by patches of abnormal skin. These areas are red, pink, or purple, dry, itchy, and scaly. Psoriasis varies in severity from small localized patches to complete b ...

. In the same month, construction was completed on Amgen's next-generation biomanufacturing facility in Singapore. Blincyto ( blinatumomab) was approved by the FDA in December of that year.

2015-2020

The company announced in March 2015 that it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15

monoclonal antibody A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Monoclonal antibodie ...

for treatment against diet nonresponsive

celiac disease Coeliac disease (British English) or celiac disease (American English) is a long-term autoimmune disorder, primarily affecting the small intestine. Patients develop intolerance to gluten, which is present in foods such as wheat, rye, spel ...

and refractory celiac disease. In August of that year, Repatha ( evolocumab) was approved by the FDA in August. In 2016, the company announced it would purchase the rights to

Boehringer Ingelheim C.H. Boehringer Sohn AG & Co. is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's List of la ...

s Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of

multiple myeloma Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibody, antibodies. Often, no symptoms are noticed initially. As it progresses, bone ...

. Also in September, the FDA approved Amjevita (

adalimumab Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn' ...

-atto). The FDA approved Parsabiv in February 2017 and Mvasi (

bevacizumab Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and use ...

-awwb) in September. Amgen began constructing a next-generation biomanufacturing plant at its West Greenwich, Rhode Island, campus in July 2018. In January 2019, Evenity ( romosozumab) received approval in Japan, followed by FDA approval in April. In June, Kanjinti (

trastuzumab Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together ...

-anns) was approved by the FDA. In November, Amgen awarded a $2 million grant to the CDC Foundation to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for their cancer treatment. In December, the FDA approved Avsola (

infliximab Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing ...

-axxq). Amgen established Amgen K.K. as the company's wholly-owned affiliate in Japan in April 2020. The company announced in July that the

United States Court of Appeals for the Federal Circuit The United States Court of Appeals for the Federal Circuit (in case citations, Fed. Cir. or C.A.F.C.) is one of the 13 United States courts of appeals. It has special appellate jurisdiction over certain categories of cases in the U.S. federa ...

had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by the

United States District Court for the District of New Jersey The United States District Court for the District of New Jersey (in case citations, D.N.J.) is a federal court in the United States Court of Appeals for the Third Circuit, Third Circuit (except for patent claims and claims against the U.S. gover ...

and rejected

Sandoz Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the ...

's attempt to invalidate the patents on Enbrel. Amgen joined the

on August 24, 2020. In September, Amgen and

Eli Lilly and Company Eli Lilly and Company, Trade name, doing business as Lilly, is an American multinational Medication, pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 count ...

announced a global manufacturing collaboration for

COVID-19 Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic. The symptoms of COVID‑19 can vary but often include fever ...

antibody therapies. Later that month, the FDA approved Riabni (

rituximab Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and ad ...

-arrx), a biosimilar to Rituxan. The company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion in March 2021. In the same month, Amgen acquired Rodeo Therapeutics for $720 million. The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer. In June, Amgen and Kyowa Kirin announced joint plans to develop and commercialize a treatment for

atopic dermatitis Atopic dermatitis (AD), also known as atopic eczema, is a long-term type of inflammation of the skin. Atopic dermatitis is also often called simply eczema but the same term is also used to refer to dermatitis, the larger group of skin conditi ...

. In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases. Amgen began construction on a new biomanufacturing plant in

New Albany, Ohio New Albany is a City (United States), city in the U.S. state of Ohio. It is located northeast of the state capital of Columbus, Ohio, Columbus. Most of the city is located in Franklin County, Ohio, Franklin County and a small portion extends i ...

, in November. In December, the FDA approved Amgen and AstraZeneca's Tezspire ( tezepelumab) for severe

asthma Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wh ...

. The FDA also approved Amgen's Otezla for adults with plaque

of any severity level. Amgen announced a research collaboration in January 2022 with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion. The company also launched a multi-target collaboration with Arrakis Therapeutics to identify novel targeted RNA degrader therapeutics. The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies. Also in February, Amgen issued its first

green bond A green bond is a fixed-income financial instrument ( bond) which is used to fund projects that have positive environmental benefits. When referring to climate change mitigation projects they are also known as ''climate bonds''. Green bonds follow ...

to fund various environmentally friendly initiatives across the company. The company broke ground on a new manufacturing facility in Holly Springs, North Carolina, in March. In August, the company agreed to acquire ChemoCentryx for $3.7 billion in an all-cash deal. ChemoCentryx is the maker of Tavneos—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associated

vasculitis Vasculitis is a group of disorders that destroy blood vessels by inflammation. Both artery, arteries and veins are affected. Lymphangitis (inflammation of lymphatic vessels) is sometimes considered a type of vasculitis. Vasculitis is primarily c ...

—which was approved last year. In December, the company announced it would acquire

Horizon Therapeutics Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the U ...

for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium) expanding its rare disease treatments. Amgen completed the acquisition of

in October 2023. In December, announced plans to use artificial intelligence in partnership with Amazon Web Services to help discover and create medicines. Amgen will use Amazon's SageMaker machine learning service to help with the manufacturing process. That same month, it was confirmed that Amgen would sponsor the 2024 Irish Open as the title sponsor.

Amgen Foundation

In October 2017, the Amgen Foundation pledged $3 million to

Khan Academy Khan Academy is an American non-profit educational organization created in 2006 by Sal Khan. Its goal is to create a set of online tools that help educate students. The organization produces short video lessons. Its website also includes suppl ...

to support the development of free online biology lessons. In July 2020, Amgen granted an additional $3 million Khan Academy to support educational equity and science learning. In January 2020, the Amgen Foundation and

Harvard University Harvard University is a Private university, private Ivy League research university in Cambridge, Massachusetts, United States. Founded in 1636 and named for its first benefactor, the History of the Puritans in North America, Puritan clergyma ...

debuted LabXchange, a free online science education platform. Amgen and the Amgen Foundation announced a commitment of up to $12.5 million to support COVID-19 relief efforts in March.

Acquisitions

*Amgen (Founded 1983 as Applied Molecular Genetics) **Synergen Inc (Acq 1994) **Kinetix Pharmaceuticals Inc (Acq 2000) **Immunex Corporation (Acq 2002) **Tularik Inc (Acq 2004) **Abgenix Inc (Acq 2006) **Avidia Inc (Acq 2006) **Alantos Pharmaceuticals (Acq 2007) **Ilypsa Inc (Acq 2007) **BioVex Group Inc (Acq 2011) **Micromet Inc (Acq 2012) **Mustafa Nevzat İlaç (Acq 2012) **KAI Pharmaceuticals (Acq 2012) **

deCODE genetics deCODE genetics () is a biopharmaceutical company based in Reykjavík, Iceland. The company was founded in 1996 by Kári Stefánsson with the aim of using population genetics studies to identify variations in the human genome associated with c ...

(Acq 2012) ** Onyx Pharmaceuticals (Acq 2013) *** Proteolix(Acq 2009) **NextCODE genetics (Spun off 2013) **Dezima Pharma (Acq 2015) **Catherex (Acq 2015) **Nuevolution AB (Acq 2019) **Otezla ( apremilast) (Acq 2019) **Five Prime Therapeutics (Acq 2021) **Rodeo Therapeutics Corporation (Acq 2021) **Teneobio (Acq 2021) **ChemoCentryx (Acq 2022) **

(Acq 2023) ***Vidara Therapeutics International (Acq 2014) ***Hyperion Therapeutics (Acq 2015) ***Crealta Holdings (Acq 2015) ***Raptor Pharmaceutical (Acq 2016) ***River Vision Development Corp. (Acq 2017) ***Viela Bio Inc (Acq 2021)

Products

Amgen's

approved drug An approved drug is a Medicine, medicinal preparation that has been validated for a therapeutic use by a Regulation of therapeutic goods, ruling authority of a government. This process is usually specific by country, unless specified otherwise. ...

s or therapeutic biologicals include: *Aimovig ( erenumab-aooe) for migraine headaches (FDA approved May 2018) *Amjevita (

) (FDA approved September 2016) *Aranesp ( darbepoetin alfa) for

anemia Anemia (also spelt anaemia in British English) is a blood disorder in which the blood has a reduced ability to carry oxygen. This can be due to a lower than normal number of red blood cells, a reduction in the amount of hemoglobin availabl ...

(FDA approval in September 2001) *Blincyto ( blinatumomab for the treatment of

acute lymphoblastic leukemia Acute lymphoblastic leukemia (ALL) is a cancer of the Lymphocyte, lymphoid line of blood cells characterized by the development of large numbers of lymphoblast, immature lymphocytes. Symptoms may include feeling tired, pale skin color, fever, ...

) *Corlanor (

ivabradine Ivabradine, sold under the brand name Procoralan among others, is a medication, which is a pacemaker current (I''f'') inhibitor, used for the symptomatic management of heart-related chest pain and heart failure. Patients who qualify for use o ...

) *Enbrel (

etanercept Etanercept, sold under the brand name Enbrel among others, is a biologic medical product that is used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF), a soluble inflammatory cytokine, by acting as a TNF inhibitor. ...

) for various forms of

arthritis Arthritis is a general medical term used to describe a disorder that affects joints. Symptoms generally include joint pain and stiffness. Other symptoms may include redness, warmth, Joint effusion, swelling, and decreased range of motion of ...

*Epogen (

) for

*Evenity ( romosozumab-aqqg) for

osteoporosis Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural deterioration of bone tissue leading to more porous bone, and consequent increase in Bone fracture, fracture risk. It is the most common reason f ...

*Imlygic (

talimogene laherparepvec Talimogene laherparepvec, sold under the brand name Imlygic among others, is a biopharmaceutical medication used to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune re ...

) for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma recurrent after initial surgery (FDA approved October 2015) *Kanjinti (

-anns) (FDA approved June 2019) *Krystexxa ( pegloticase) *Kyprolis ( carfilzomib) *Lumakras ( sotorasib) *Mvasi (

-awwb) *Neulasta ( pegfilgrastim) for

neutropenia Neutropenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood. Neutrophils make up the majority of circulating white blood cells and serve as the primary defense against infections by destroying bacteria ...

(FDA approved 2002) *Neupogen (

) for

*Nplate ( romiplostim) for chronic immune thrombocytopenic purpura (FDA approved 2008) *Otezla ( apremilast) *Parsabiv ( etelcalcetide) *Prolia (

denosumab Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastasis, metastases to bone, and giant cell tumor of bone. The most common side ef ...

) for postmenopausal

*Repatha ( evolocumab) *Riabni (

-arrx) *Sensipar/Mimpara ( cinacalcet for primary and secondary hyperparathyroidism, a mineral metabolism complication common in patients with kidney failure) (FDA approved 2004) *Tepezza ( teprotumumab) *Tezspire ( tezepelumab-ekko) *Tavneos ( avacopan) *Uplizna ( inebilizumab) *Vectibix ( panitumumab for

colon cancer Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). Signs and symptoms may include blood in the stool, a change in bowel ...

) (FDA approved 2006) *Xgeva (

) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone in adults with bone metastases from solid tumors)

Products developed and then sold off

* Kepivance (

palifermin Palifermin (trade name Kepivance, marketed by Biovitrum) is a truncated human recombinant keratinocyte growth factor (KGF) produced in ''Escherichia coli''. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tra ...

for oral mucositis, sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008Amgen press office
Biovitrum Closes Product Acquisition Deal with Amgen
*StemGen ( ancestim) for use in combination with

for mobilizing peripheral

hematopoietic stem cells Hematopoietic stem cells (HSCs) are the stem cells that give rise to other blood cells. This process is called haematopoiesis. In vertebrates, the first definitive HSCs arise from the ventral endothelial wall of the embryonic aorta within the ...

) (sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008) *Kineret ( anakinra) for

rheumatoid arthritis Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects synovial joint, joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and h ...

, exclusively licensed to Biovitrium, now Swedish Orphan Biovitrum, in December 2008 In 2019, the company's largest selling products were Enbrel (

), a

tumor necrosis factor Tumor necrosis factor (TNF), formerly known as TNF-α, is a chemical messenger produced by the immune system that induces inflammation. TNF is produced primarily by activated macrophages, and induces inflammation by binding to its receptors o ...

blocker used in the treatment of

and other autoimmune diseases, and Neulasta ( pegfilgrastim), an

immunostimulator Immunostimulants, also known as immunostimulators, are substances (drugs and nutrients) that stimulate the immune system usually in a non-specific manner by inducing activation or increasing activity of any of its components. One notable example i ...

used to prevent infections in patients undergoing cancer

chemotherapy Chemotherapy (often abbreviated chemo, sometimes CTX and CTx) is the type of cancer treatment that uses one or more anti-cancer drugs (list of chemotherapeutic agents, chemotherapeutic agents or alkylating agents) in a standard chemotherapy re ...

Pipeline and clinical trials

As of August 2022, Amgen had 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. In September 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic

non-small-cell lung carcinoma Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitiv ...

(NSCLC) with the KRAS G12C mutation. In August 2020, Amgen, Takeda, and

AbbVie AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the ...

, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen. In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (including

immunotherapy Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as ''activation immunotherapies,'' while immunotherap ...

and/or chemotherapy). Amgen, the Global Coalition for Adaptive Research, and Eisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19. In November 2020, Amgen, Takeda, and UCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19. Amgen also announced that it would terminate its collaboration with Cytokinetics and transition the development and commercialization rights for omecamtiv mecarbil and AMG 594. Amgen and

announced positive topline results from a Phase 3 trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma. In December 2020, the FDA granted breakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation. In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation. Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe and Japan. In September 2022, data from a late-stage study showed the company's cancer pill Lumakras beating out chemotherapy. This was the first approved drug in the set of treatments that target KRAS, among the most common generic mutations found in cancers but one where researchers have struggled for years to design drugs to treat. The drug was approved in 2021 with a list price of $17,900 per month. In March 2025, data for the drug Tezspire, showed the best results for treating chronic rhinosinusitis with nasal polyps. In the same month, Amgen announced the start of two late-stage trials for MariTide, a weight loss drug.

Carbon footprint

Amgen reported Total CO2e emissions (Direct + Indirect) for the twelve months ending 31 December 2020 at 243 Kt (-6 /-2.4% y-o-y)Alt URL
/ref> and aims to reach net zero emissions by 2027.

Controversies

In December 2012 Amgen plead guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related

whistleblower Whistleblowing (also whistle-blowing or whistle blowing) is the activity of a person, often an employee, revealing information about activity within a private or public organization that is deemed illegal, immoral, illicit, unsafe, unethical or ...

complaints. Federal prosecutors accused the company of pursuing profits while putting patients at risk.

Public-private engagement

Amgen engages with the public and private sectors in a variety of settings including to promote

research and development Research and development (R&D or R+D), known in some countries as OKB, experiment and design, is the set of innovative activities undertaken by corporations or governments in developing new services or products. R&D constitutes the first stage ...

, academic funding, event sponsorship,

philanthropy Philanthropy is a form of altruism that consists of "private initiatives for the Public good (economics), public good, focusing on quality of life". Philanthropy contrasts with business initiatives, which are private initiatives for private goo ...

, and political lobbying.

Academia

Institute for Advanced Study The Institute for Advanced Study (IAS) is an independent center for theoretical research and intellectual inquiry located in Princeton, New Jersey. It has served as the academic home of internationally preeminent scholars, including Albert Ein ...

- Donor to various IAS campaigns, including the IAS/Park City Mathematics Institute (PCMI), the Regional Initiative in Science and Education (RISE), and the Opportunity Equation (OE). * LA Promise Fund - Sponsor of the Amgen Biotech Experience Los Angeles (ABE-LA). *

University of Toronto The University of Toronto (UToronto or U of T) is a public university, public research university whose main campus is located on the grounds that surround Queen's Park (Toronto), Queen's Park in Toronto, Ontario, Canada. It was founded by ...

- Donor to U of T's Boundless campaign. *

University of Washington The University of Washington (UW and informally U-Dub or U Dub) is a public research university in Seattle, Washington, United States. Founded in 1861, the University of Washington is one of the oldest universities on the West Coast of the Uni ...

- Donor.

Events and conferences

* Alberta Kidney Days - Virtual series sponsor. * BC Kidney Days - Sponsor. * Mentoring in IBD - Sponsor. * Princess Margaret Cancer Centre (PMCC) Conference - Sponsor.

Health care

* Kingston General Hospital - Donor. * Princess Margaret Cancer Centre - Donor to the Princess Margaret Cancer Foundation. * Providence Health Care - Donor. *

Scarborough Health Network Scarborough Health Network (SHN) is a hospital network in Scarborough, Toronto, Scarborough, Toronto, Ontario, Canada. It operates the Scarborough General Hospital (Toronto), Scarborough General, Centenary Hospital, Centenary, and Birchmount Hospit ...

- Donor to the SHN Foundation. *

SickKids The Hospital for Sick Children, corporately branded as SickKids, is a major paediatric hospital, pediatric teaching hospital located on University Avenue (Toronto), University Avenue in Toronto, Ontario, Canada. Affiliated with the University of ...

- Donor to the SickKids Foundation. * Sinai Health System - Donor to the Sinai Health Foundation. * St. Michael's Hospital - Donor. *

Sunnybrook Health Sciences Centre Sunnybrook Health Sciences Centre (SHSC), commonly known as Sunnybrook Hospital or simply Sunnybrook, is an academic health science centre located in Toronto, Ontario, Canada. The hospital is the largest trauma centre in Canada. It is accredite ...

- Donor to the Sunnybrook Foundation. *

Unity Health Toronto Unity Health Toronto is a Catholic Church and health care, Catholic hospital network serving Toronto, Ontario, Canada. It was initially founded in 2017 under the provisional name Our Shared Purpose through the merger of St. Michael's Hospital (Tor ...

- Donor. * University Health Network - Donor to the UHN Foundation. *

Women's College Hospital Women's College Hospital is a teaching hospital in Toronto, Ontario, Canada. It is located in downtown Toronto at the north end of Hospital Row, a section of University Avenue where several major hospitals are located. It currently functions ...

- Donor.

Media

National Geographic Society The National Geographic Society, headquartered in Washington, D.C., United States, is one of the largest nonprofit scientific and educational organizations in the world. Founded in 1888, its interests include geography, archaeology, natural sc ...

- Donor.

Medical societies

* American Society of Hematology - Corporate funder. * Arthritis Society (Canada) - Partner. * Canadian Society of Hospital Pharmacists - Donor to the CSHP Foundation. * Canadian Society of Nephrology - Corporate partner. *

Endocrine Society The Endocrine Society is a professional, international medical organization in the field of endocrinology and metabolism, founded in 1916 as The Association for the Study of Internal Secretions. The official name of the organization was changed t ...

- Corporate liaison board member. *

European Society of Cardiology The European Society of Cardiology (ESC) is an independent Nonprofit organisation, non-profit, non-governmental professional association that works to advance the prevention, diagnosis and management of diseases of the heart and blood vessels, a ...

- Sponsor for the EORP registry programme. * Federation of Medical Women in Canada - Sponsor.

Political lobbying

* Alliance for a Stronger FDA - Member. * Alliance for Aging Research - Donor. *

BIOTECanada BIOTECanada, previously the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and inter ...

- Member. *

Bipartisan Policy Center The Bipartisan Policy Center (BPC) is a Washington, D.C.–based think tank that promotes bipartisanship. The organization aims to combine ideas from both the Republican and Democratic parties to address U.S. policy challenges. History BPC w ...

- Donor. *

The Business Council The Business Council is a nonpartisan organization of business leaders headquartered in Washington, D.C.Robert A. Bradway. * CDC Foundation - Funding partner. * Centre for Commercialization of Regenerative Medicine (CCRM) - Industry partner. *

Council on Foreign Relations The Council on Foreign Relations (CFR) is an American think tank focused on Foreign policy of the United States, U.S. foreign policy and international relations. Founded in 1921, it is an independent and nonpartisan 501(c)(3) nonprofit organi ...

- Affiliate. *

European Federation of Pharmaceutical Industries and Associations The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association and lobbying organisation, founded in 1978 and representing the pharmaceutical industry operating in Europe. Through its membershi ...

(EFPIA) - Member. *

Foundation for the National Institutes of Health The Foundation for the National Institutes of Health (FNIH) is a not-for-profit, 501(c)(3) charitable organization established by the US Congress in 1990. Located in North Bethesda, MD, the FNIH raises private-sector funds, and creates and manage ...

(FNIH) - Donor. * Global Health Progress - Partner. GHP is a multinational resource hub hosted by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). * Health Products Stewardship Association - Member. * Innovative Medicines Canada - Member company. * International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) - Member. * Life Sciences British Columbia - Sponsor. * Mayor's Fund for Los Angeles - Disaster relief grant provider. * National Health Council - Member. * Personalized Medicine Coalition - Member. * Pharmaceutical Advertising Advisory Board (PAAB) - Client. PAAB "maintains a collaborative relationship” with

Health Canada Health Canada (HC; )Health Canada is the applied title under the Federal Identity Program; the legal title is Department of Health (). is the Structure of the Canadian federal government#Departments, with subsidiary units, department of the Gove ...

. *

Pharmaceutical Research and Manufacturers of America Pharmaceutical Research and Manufacturers of America (PhRMA, pronounced ), formerly known as the Pharmaceutical Manufacturers Association, is an American trade group representing companies in the pharmaceutical industry. Founded in 1958, PhRMA ...

(PhRMA) - Member. * Reagan-Udall Foundation for the Food and Drug Administration - Donor. * Research!America - Member.

Professional associations

* British Columbia Pharmacy Association - Sponsor. * Canadian Association of Gastroenterology - Corporate sponsor. * Canadian Association of Radiologists - Corporate partner. * Canadian Rheumatology Association - Corporate sponsor. * Canadian Urological Association - Corporate sponsor. * Colorectal Cancer Canada - Sponsor. *

Ontario Medical Association The Ontario Medical Association (OMA) is a membership organization that represents the political, clinical and economic interests of Ontario physicians. Practising physicians, Residency (medicine), residents, and Medical school, medical students en ...

- Donor.

Research and development

* Alberta Kidney Disease Network - Grant provider. * Can-SOLVE CKD Network - Funding partner. *

Urban Institute The Urban Institute is a Washington, D.C.–based think tank that conducts economic and social policy research to "open minds, shape decisions, and offer solutions". The institute receives funding from government contracts, foundations, and p ...

- Donor.

Awards and recognition

Amgen was ranked 151 on the Fortune 500 list of the largest United States corporations by revenue in 2024.

References

External links

* * {{Authority control Biotechnology companies of the United States Pharmaceutical companies Companies based in Thousand Oaks, California Companies listed on the Nasdaq Companies in the Dow Jones Industrial Average Companies in the Dow Jones Global Titans 50 Life sciences industry Multinational companies headquartered in the United States Pharmaceutical companies established in 1980 Biotechnology companies established in 1980 Pharmaceutical companies of the United States 1980 establishments in California 1980s initial public offerings

History

2000-2014

2015-2020

Amgen Foundation

Acquisitions

Products

Products developed and then sold off

Pipeline and clinical trials

Carbon footprint

Controversies

Public-private engagement

Academia

Events and conferences

Health care

Media

Medical societies

Political lobbying

Professional associations

Research and development

Awards and recognition

See also

References

External links